Choosing Your Treatment Path for Localized Cancer

Deciding how to treat localized prostate cancer is a process of balancing “oncologic control”—eliminating or controlling the cancer—with your “quality of life,” specifically regarding urinary, bowel, and sexual function ^[1]. Because many prostate cancers grow slowly, the “best” treatment is highly dependent on your specific risk group, life expectancy, comorbidities, and personal priorities.

The Localized Treatment Decision Tree

The choice of treatment generally follows your NCCN risk category:

• Low / Very-Low Risk: Active Surveillance is generally the preferred standard ^[1].
• Favorable Intermediate Risk: Active Surveillance is considered for selected patients, though definitive treatment (Surgery or Radiation) is often discussed ^[2].
• Unfavorable Intermediate Risk: Definitive treatment is usually recommended. This typically involves Surgery (Radical Prostatectomy) OR Radiation combined with short-course hormone therapy ^[3][4].
• High / Very-High Risk: Intensive multimodality treatment is usually considered. This includes Surgery OR Radiation combined with long-course hormone therapy (and potentially a brachytherapy boost) ^[5][6].

(Note: Hormone therapy (ADT) is not routinely paired with radical prostatectomy as a primary treatment, though surgery may be part of a planned multi-step strategy in specific high-risk cases).

Active Surveillance vs. Watchful Waiting

Active surveillance is a proactive monitoring plan designed to avoid the side effects of treatment while keeping a close eye on the cancer so you can act if it progresses ^[1].

• The Protocol: While protocols vary, they generally involve regular PSA testing (e.g., every 6 months) and physical exams. Confirmatory MRIs and biopsies are used to ensure the cancer remains low-risk ^[7][8].
• Triggers for Treatment: A rising PSA alone does not automatically trigger treatment; it prompts reassessment. Transitioning to active treatment is usually triggered by a biopsy showing a higher Grade Group, increased tumor volume, or distinct progression on an MRI ^[9].

This is distinctly different from watchful waiting, which involves less intensive monitoring focused on managing symptoms rather than aiming to cure the disease, often recommended for individuals with limited life expectancy or significant other health issues.

Definitive Treatments: Surgery and Radiation

1. Radical Prostatectomy (Surgery)

This involves removing the entire prostate gland. In patients whose estimated risk justifies it, the surgeon may also perform a pelvic lymph-node dissection to remove nearby lymph nodes. Surgery provides a clear pathology report of the entire tumor, but carries risks of urinary incontinence, erectile dysfunction, and surgical complications ^[10].

2. Radiation Therapy

Radiation uses high-energy beams to kill cancer cells. It can be delivered in two main ways:

• External Beam Radiation (EBRT/SBRT): Delivered from outside the body over several days or weeks ^[10].
• Brachytherapy: This involves placing radioactive “seeds” (LDR) or a temporary radioactive source (HDR) directly into the prostate ^[11].
  • Brachytherapy Boost: For some intermediate and high-risk patients, a brachytherapy dose is added to EBRT. This improves biochemical control (lowers the chance of PSA recurrence) but carries higher risks of short-term urinary toxicity. Better biochemical control does not guarantee an overall survival benefit, making patient selection critical ^[12][13].

The Role of Hormone Therapy (ADT) in Localized Disease

Androgen Deprivation Therapy (ADT) lowers your testosterone to “starve” the cancer cells. In localized disease, it is primarily used in combination with radiation to make the treatment more effective ^[4].

• Unfavorable Intermediate Risk: Short-course ADT is typically used alongside radiation ^[4].
• High / Very-High Risk: Long-course ADT is the standard with radiation ^[14][15].

Side effects of ADT go beyond hot flashes and fatigue. They include loss of muscle mass, changes in body composition, insulin and lipid profile changes, bone loss, sexual dysfunction, anemia, and possible cardiovascular risk ^[13]. Your care team will conduct baseline assessments to mitigate these risks.

Shared Decision Making

There is no single “right” answer. In appropriately selected localized groups, surgery and modern radiation show broadly comparable long-term survival rates, but they differ significantly in progression risk, recovery time, and toxicity profiles ^[5][16]. Your decision requires a thorough discussion with both a Urologist and a Radiation Oncologist.